[go: up one dir, main page]

PE20020386A1 - Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa - Google Patents

Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa

Info

Publication number
PE20020386A1
PE20020386A1 PE2001000814A PE2001000814A PE20020386A1 PE 20020386 A1 PE20020386 A1 PE 20020386A1 PE 2001000814 A PE2001000814 A PE 2001000814A PE 2001000814 A PE2001000814 A PE 2001000814A PE 20020386 A1 PE20020386 A1 PE 20020386A1
Authority
PE
Peru
Prior art keywords
glucokinase activators
phenyl
tetrazolil
cyclopentil
tetrazol
Prior art date
Application number
PE2001000814A
Other languages
English (en)
Inventor
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020386A1 publication Critical patent/PE20020386A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN TETRAZOL DE FORMULA I Y IA ENTRE OTROS DONDE Z ES EL GRUPO a; UNO DE R1 O R2 ES EL GRUPO b Y EL OTRO ES H, HALO, ALQUILO, SULFONILO, ENTRE OTROS; R3 ES CICLOALQUILO; R4 ES -C(O)-NHR6, ANILLO HETEROAROMATICO DE 5 A 6 MIEMBROS, ENTRE OTROS; R5 ES ALQUILO, PERFLUORO ALQUILO; R6 ES H, ALQUILO; n ES 0-1; -- SIGNIFICA UNA CONFIGURACION TRANS A TRAVES DEL DOBLE ENLACE; * ES EL ATOMO DE CARBONO ASIMETRICO. SON COMPUESTOS PREFERIDOS (E)-N-(5-BROMO-PIRIDIN-2-IL)-3-CICLOPENTIL-2-[3-FLUORO-4-(5-METIL-TETRAZOL-1-IL)-FENIL]-ACRILAMIDA, (E)-3-CICLOPENTIL-2-[4-(5-METIL-TETRAZOL-1-IL)-3-TRIFLUOROMETIL-FENIL]-N-TIZAOL-IL-ACRILAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON ACTIVADORES DE LA GLUCOQUINASA CAPACES DE AUMENTAR LA SECRECION DE INSULINA Y SON UTILES PARA EL TRATAMIENTO DE DIABETES TIPO II
PE2001000814A 2000-08-15 2001-08-15 Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa PE20020386A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
PE20020386A1 true PE20020386A1 (es) 2002-05-13

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000814A PE20020386A1 (es) 2000-08-15 2001-08-15 Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa

Country Status (20)

Country Link
US (3) US6369232B1 (es)
EP (1) EP1311504B1 (es)
JP (1) JP3961948B2 (es)
KR (1) KR100518061B1 (es)
CN (1) CN1209362C (es)
AR (1) AR031718A1 (es)
AT (1) ATE297921T1 (es)
AU (2) AU8399801A (es)
BR (1) BR0113312A (es)
CA (1) CA2419416C (es)
DE (1) DE60111540T2 (es)
DK (1) DK1311504T3 (es)
ES (1) ES2243541T3 (es)
MX (1) MXPA03001275A (es)
PA (1) PA8525201A1 (es)
PE (1) PE20020386A1 (es)
PT (1) PT1311504E (es)
UY (1) UY26885A1 (es)
WO (1) WO2002014312A1 (es)
ZA (1) ZA200300904B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
CA2498089A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
CN101098876A (zh) * 2004-04-02 2008-01-02 诺瓦提斯公司 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法
CN1960995B (zh) * 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてglk活性化剤として使用するためのヘテロアリールベンズアミド誘導体
NZ564743A (en) * 2005-07-11 2010-03-26 Mitsubishi Tanabe Pharma Corp An oxime derivative as a glucokinase activating agent and preparations thereof
KR20080040046A (ko) 2005-08-31 2008-05-07 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
AU2006310474A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
ES2381864T3 (es) * 2005-12-15 2012-06-01 Nihon Nohyaku Co., Ltd. Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ATE522518T1 (de) * 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
JP5207981B2 (ja) * 2007-01-10 2013-06-12 田辺三菱製薬株式会社 ヒドラゾン誘導体
EP2116533B1 (en) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
CN101827832B (zh) * 2007-10-08 2014-05-07 阿德维纳斯治疗私人有限公司 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
EP2236498A4 (en) * 2008-01-18 2012-02-22 Astellas Pharma Inc PHENYLACETAMIDE DERIVATIVE
RU2565070C2 (ru) * 2008-04-28 2015-10-20 Киорин Фармасьютикал Ко., Лтд. Производное циклопентилакриламида
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
JP2001509166A (ja) * 1997-01-28 2001-07-10 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のためのβ▲下3▼作動薬としてのチアゾールベンゼンスルホンアミド
CZ301366B6 (cs) * 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem

Also Published As

Publication number Publication date
AU2001283998B2 (en) 2005-10-20
CN1209362C (zh) 2005-07-06
ZA200300904B (en) 2004-04-30
KR20030022408A (ko) 2003-03-15
JP3961948B2 (ja) 2007-08-22
JP2004506632A (ja) 2004-03-04
ES2243541T3 (es) 2005-12-01
KR100518061B1 (ko) 2005-09-28
CA2419416A1 (en) 2002-02-21
MXPA03001275A (es) 2003-06-30
US6441180B1 (en) 2002-08-27
WO2002014312A1 (en) 2002-02-21
US20020035267A1 (en) 2002-03-21
ATE297921T1 (de) 2005-07-15
PA8525201A1 (es) 2002-07-30
DK1311504T3 (da) 2005-10-17
EP1311504B1 (en) 2005-06-15
DE60111540D1 (de) 2005-07-21
BR0113312A (pt) 2003-07-01
US6369232B1 (en) 2002-04-09
AU8399801A (en) 2002-02-25
EP1311504A1 (en) 2003-05-21
CA2419416C (en) 2009-10-13
UY26885A1 (es) 2002-02-28
US6388088B1 (en) 2002-05-14
CN1466584A (zh) 2004-01-07
US20020035266A1 (en) 2002-03-21
AR031718A1 (es) 2003-10-01
DE60111540T2 (de) 2006-03-16
US20020065275A1 (en) 2002-05-30
PT1311504E (pt) 2005-10-31

Similar Documents

Publication Publication Date Title
PE20020386A1 (es) Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa
PE20011310A1 (es) Alquinil fenil amidas heteroaromaticas como activadores de la glucokinasa
PE20020056A1 (es) Fenil amidas para-aril o heteroaril sustituidas como activadores de la glucoquinasa
PE20030968A1 (es) Derivados de 5-feniltiazol como inhibidores de cinasas
AR041467A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
PE20020049A1 (es) Fenilamidas para amina sustituidas como activadores de glucoquinasa
AR032752A1 (es) Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa
PE20011313A1 (es) Activadores de glucoquinasa que contienen hidantoina
PE20021066A1 (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, asi como preparados farmaceuticos que las contienen
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
PE20210040A1 (es) Moduladores de la via de estres integrada
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
PE20030704A1 (es) Derivados de pirrolidina
PE20020504A1 (es) N-acilsulfonamidas promotoras de apoptosis
PE20020335A1 (es) Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
AR038476A1 (es) Derivados de quinazolina
MY136926A (en) Glucokinase activators
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed